Treatment with chemotherapeutics agents may induce persistent DNA damage in male germ cells with the possibility of longterm consequences on fertility and progeny outcome. Telomeres, specialized structures at the physical ends of chromosomes, play an important role in the maintenance of genetic stability and in the response of somatic cells to anticancer drugs. Our objective was to test the hypothesis that exposure to bleomycin, etoposide, or cisplatin (the drugs used to treat testicular cancer) or cyclophosphamide (an anticancer agent and immunosuppressant) targets telomeres in the male germ line. C18-4 spermatogonial cells were exposed to bleomycin, etoposide, cisplatin, or 4-hydroperoxycyclophosphamide (4OOH-CPA, a preactivated analog of cyclophosphamide). All four anticancer drugs induced a significant increase in DNA damage in C18-4 cells, as assessed by gamma-H2AX immunofluorescence. Interestingly, the gamma-H2AX signal was localized to telomeres after treatment with bleomycin, cisplatin, and 4OOH-CPA, but not etoposide. Mean telomere lengths, the intensity of the telomere fluorescence in situ hybridization signal, telomerase activity, and the expression of the telomerase enzyme mRNA components, Tert and Terc, were reduced by exposure to cisplatin and 4OOH-CPA, but not by bleomycin or etoposide. Thus, although all four anticancer drugs induced DNA damage in this spermatogonial cell line, telomeres were not specifically affected by etoposide and only the two alkylating agents, cisplatin and 4OOH-CPA, induced telomere dysfunction. This telomere dysfunction may contribute to infertility and developmental defects in the offspring. alkylating agents, anticancer drugs, cell culture, DNA double strand breaks, fluorescence in situ hybridization,
INTRODUCTION
Treatment of males with anticancer drugs, such as cyclophosphamide, bleomycin, etoposide, and cisplatin, causes a range of adverse outcomes in their progeny, including an increase in the rate of formation of micronuclei in 2-cell embryos and increases in preimplantation and postimplantation loss, growth retardation, congenital malformations, and postnatal death [1] [2] [3] [4] [5] . Telomere shortening is also associated with elevated rates of early developmental failure and an increase in micronuclei [6, 7] . The effects of chemotherapeutic agents on telomeres in the male germline have not been studied.
Telomeres, located at the termini of linear chromosomes of most eukaryotic organisms, contain repetitive DNA sequences (tandem repeats of TTAGGG) and are of critical importance in the maintenance of chromosome stability in both somatic and germ cells [8] [9] [10] and in the regulation of chromosome position within nuclei [11] [12] [13] . Telomere length can be shortened by loss of telomerase and cell division [14] . DNA damage can also irreparably injure telomeres [15] .
DNA-damaging agents are among the most effective anticancer agents in clinical use; these include alkylating agents (e.g., cyclophosphamide, cisplatin), antimetabolites (e.g., 5-fluorouracil), topoisomerase inhibitors (e.g., etoposide), and cytotoxic antibiotics (e.g., bleomycin) [16] . Most of these drugs cause DNA damage, inducing cross-links as well as single and double strand breaks [16] . Etoposide [17] [18] [19] , bleomycin [20, 21] , and cisplatin [22] have been reported to affect telomerase activity in human somatic cells. Failure to repair the DNA damage caused by anticancer drugs may have adverse effects on subsequent generations of exposed cells. If these cells are germ cells, progeny may be affected.
During spermatogenesis, the self-renewal of spermatogonia supports seminiferous epithelium maintenance [23] . Spermatogonia are responsible for the lifelong production of spermatozoa and for the transmission of genetic information to the next generation [24] .Using a spermatogonial cell line (C18-4 cells) as a model to evaluate toxicity in vitro [25] , we tested the hypothesis that anticancer drugs induce DNA damage and affect telomere length in spermatogonial cells by modulation of telomerase activity.
MATERIALS AND METHODS

Cell Culture and Treatments
The C18-4 spermatogonial cell line was a gift from Dr. M.C. Hofmann [23, 25] . Cells were plated at a density of 2000 cells/ml in four-well Lab-Tek chamber slides (Thermo Fisher Scientific) in culture medium composed of 87.5% Dulbecco modified Eagle medium (Wisent), 10% fetal bovine serum (Wisent), 1 mM sodium pyruvate (Wisent), 0.5% penicillin/streptomycin 100X (Wisent) and 1% nonessential amino acids 100X (Wisent). All cultures were maintained at 348C in a humidified chamber with 5% CO 2 in air. Chemotherapeutic drugs, bleomycin sulfate (LKT Laboratories), etoposide (LKT Laboratories), cisplatin (LKT Laboratories), or 4-hydroperoxycyclophosphamide (4OOH-CPA; Niomech), were added on Day 4 postplating. The stock solution of each drug was prepared in 100% dimethyl sulfoxide (DMSO; Thermo Fisher Scientific) and then diluted to the desired concentration prior to use. The concentrations of the drugs in the stock solutions were 40 mM for cisplatin, 50 mM for etoposide, and 100 mM for bleomycin. The 4OOH-CPA was prepared fresh just before use. The final DMSO concentration in the media of all drug assays was 0.1 % (v/v). Control cultures received 0.1% DMSO only. The effects of these drugs were assessed 48 h later. Cell survival was assessed using the trypan blue exclusion test [26] . Live cells possessed intact cell membranes that excluded trypan blue and were counted using a hemocytometer.
Indirect Immunofluorescence and ImmunoFISH
Indirect immunofluorescence was done as previously described [27] . C18-4 cells were fixed with 4% paraformaldehyde in PBS for 40 min and permeabilized with 0.2% Triton X-100 in PBS for 20 min at 378C. After blocking in PBS containing calf serum for 2 h, samples were incubated overnight with a 1:1000 dilution of antibodies against cH2AX (Millipore Canada Ltd.) at 48C. Samples were then incubated with anti-mouse IgG secondary antibody Alexa 488 (Life Technologies) at a 1:1000 dilution for 1 h at room temperature. ImmunoFISH was done using a telomere PNA FISH kit (PNA Bio) in accordance with the manufacturers' instructions. C18-4 cells were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI; 0.1 lg/ml in PBS). Images were acquired using a multiphoton Leica TCS SP8 MP microscope and LAS AF Lite software by acquisition of optical z sections at different levels along the optical axis (resolution 2488 3 2488, three sections with total distance 1.76 lm). Colocalization between cH2AX and telomeres in each channel was assessed using Imaris software (Bitplane) on confocal threedimensional stacks. Two points were considered as colocalized if their respective intensities were higher than the threshold of their channels, and if their ratios (of intensity) were higher than the ratio setting value. Comparative immunofluorescence analyses were done in parallel with identical acquisition parameters. Telomere length was also analyzed by quantification of telomeric signal fluorescence intensities using Imaris software.
DNA Extraction and Quantification of Telomere Length
Genomic DNA was extracted from C18-4 cells using a QIAamp DNA Mini Kit (Qiagen Ltd.) according to the manufacturer's recommendations. Telomere length was determined by quantitative PCR, as previously described [28, 29] . Briefly, two PCRs were done for each sample, one to determine the cycle threshold (Ct) value for telomere amplification with the telomeric primers (forward 5 0 -CGG TTT GTT TGG GTT TGG GTT TGG GTT TGG GTT TGG GTT-3 0 and reverse 5 0 -GGC TTG CCT TAC CCT TAC CCT TAC CCT TAC CCT TAC CCT-3 0 ) and the other to determine the Ct value for the amplification of a single-copy control gene 36B4 (forward 5 0 -ACT GGT CTA GGA CCC GAG AAG-3 0 and reverse 5 0 -TCA ATG GTG CCT CTG GAG ATT-3 0 ). Each sample was run in triplicate, and each PCR was done using 20 ng of DNA sample in 25 ll final reaction volume. Mean Ct values were used to calculate the relative telomere length using the telomere:single copy gene (T:S) ratio [28] .
Telomerase Activity
The telomerase activity in C18-4 cells was detected using a TRAPeze telomerase detection kit (S7700-KIT; Intergen Company) according to the manufacturer's instructions. In brief, C18-4 cells were suspended in CHAPS lysis buffer (TRAPeze telomerase detection kit) for 30 min on ice. The suspension was centrifuged at 12 000 g for 20 min. Protein concentrations were determined using the BioRad protein assay kit according to the manufacturer's protocol (BioRad). Samples (0.01-1.00 lg protein) were incubated with telomere repeat amplification protocol (TRAP) buffer (TRAPeze telomerase detection kit) supplemented with dNTP mix (Takara Bio Inc.), TS primer (TRAPeze telomerase detection kit), TRAP primer mix (TRAPeze telomerase detection kit) and Taq polymerase (Takara Bio Inc.) in distilled water at 308C for 30 min. PCR was done at 948C for 30 sec, 588C for 30 sec for 35 cycles using an ABI Step One sequence detection system (Applied Biosystems). Changes in DF: fluorescein (representing the amount of product) and DS: sulforhodamine (as the internal control) were read with a fluorescence microplate reader (SPECTRA MAX Plus; Molecular Devices Corporation).
RNA Extraction and Quantitative RT-PCR
Total RNA was extracted from samples using the RNeasy Plus Micro Kit with on-column DNase digestion (Qiagen Ltd.). Random primed cDNA was prepared using the PrimeScriptTM RT Master Mix (Takara Bio Inc.). Primer sequences were as follows: for telomerase RNA component (Terc) forward 5
-A A G C T G G C T G C T C A T T C T G T -3
0 a n d r e v e r s e 5 0 -A T G G T CATTGTCGCCTCTGG-3 0 ; for telomerase reverse transcriptase (Tert) forward 5 0 -AA G C T GG C T G C T C AT T C TG T -3 0 a n d r e v e r s e 5 0 -A TG G T CATTGTCGCCTCTGG-3 0 ; for 18s rRNA (as internal control) 5 0 -AAACGGCTACCACATCCAAG-3 0 forward 18s and 5 0 -CCTCCAATG GATCCTCGTTA-3 0 reverse 18s. Quantitative RT-PCR was done using the ABI Step One sequence detection system (Applied Biosystems) using the following thermal cycling conditions: 30 sec at 958C, followed by 40 cycles of 5 sec at 958C, 31 sec at 558C, and 30 sec at 728C. Beta-actin was amplified in parallel as a loading control.
Statistical Analysis
All experiments were repeated at least three times. All data represent the means plus or minus the SEM. The differences between treatment and control groups were analyzed using one-way ANOVA Stata Software 11.0 (Stata Corporation). Values of P , 0.05 were considered to be statistically significant.
RESULTS
Survival of C18-4 Spermatogonial Cells after Exposure to Chemotherapeutic Drugs
The survival of C18-4 spermatogonial cells after treatment with each of the four chemotherapeutic drugs was assessed using the trypan blue exclusion test (Fig. 1) . The concentrations of 4OOH-CPA tested ranged from 0.01 to 50 lM; the half maximal inhibitory concentration (IC 50 ) of 4OOH-CPA was 1.61 lM. For cisplatin treatment, concentrations ranging from 0.01 to 20 lM were used; the IC 50 for cisplatin treatment was 1.06 lM. The concentrations of etoposide tested ranged from 0.005 to 5 lM and the IC 50 was 0.059 lM. Unexpectedly, C18-4 spermatogonial cells showed relative resistance to bleomycin; cell numbers were not reduced until they were exposed to 50 lM bleomycin. The effects of all four anticancer drugs on telomere function and DNA damage were analyzed at concentrations at which spermatogonial stem cell survival exceeded 92% (Table 1) .
C18-4 Spermatogonial Cell Telomere Lengths Were Significantly Shortened after Cisplatin and 4OOH-CPA Treatment
Mean telomere length was assessed using quantitative PCR by determining the T:S ratio. Telomere lengths were shortened significantly after treatment with 0.1 lM cisplatin ( Fig. 2A) or 0.1 lM 4OOH-CPA (Fig. 2B) ; neither etoposide treatment (Fig. 2C ) nor bleomycin treatment (Fig. 2D ) affected telomere length. Telomere fluorescence in situ hybridization (FISH) signals were quantified to represent telomere lengths. The intensity of the FISH signal was decreased after treatment with 0.1 lM cisplatin (see Fig. 4B ) or 0.1 lM 4OOH-CPA (see Fig.  5B ) but not after treatment with either etoposide (see Fig. 6B ) or bleomycin (see Fig. 7B ). These results provide confirmation that cisplatin and 4OOH-CPA treatments shortened telomere lengths.
Effects of Anticancer Drugs on C18-4 Spermatogonial Cell Telomerase Function as Assessed by Telomerase Activity and mRNA Concentrations
The TRAP assay was used to assess effects on telomerase activity. Telomerase activity was significantly reduced after treatment with 0.1 lM cisplatin or 0.1 lM 4OOH-CPA, but was not affected by treatment with etoposide or bleomycin (Fig. 3A) . Quantitative RT-PCR analysis revealed that steadystate concentrations of Tert were reduced significantly after treatment with 0.1 lM cisplatin or 0.1 lM 4OOH-CPA, but not significantly changed after treatment with etoposide or bleomycin (Fig. 3B) . Concentrations of Terc were reduced significantly after treatment with 0.1 lM cisplatin or 0.1 lM 4OOH-CPA, not significantly changed after treatment with 
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etoposide, and increased after treatment with 5 lM bleomycin (Fig. 3C ).
The Induction of DNA Damage in the Telomere Region in C18-4 Spermatogonial Cells after Treatment with Cisplatin, 4OOH-CPA, or Bleomycin
The localization of immunofluorescent cH2AX foci, a marker for DNA double strand breaks, was determined as a measure of DNA damage in spermatogonial cells exposed to concentrations of the anticancer drug at which !92% of the cells survived (Table 1 ). The cH2AX signal intensity was increased significantly after treatment with 0.03 or 0.1 lM cisplatin (Fig. 4, A and C) ; interestingly, this cH2AX signal was highly colocalized with the telomere FISH probe, revealing that DNA damage was increased significantly within the telomere region (Fig. 4, A and D) . Similar results were observed in the cells after 4OOH-CPA treatment. The signal intensity of cH2AX was significantly increased after treatment with 0.03 lM or 0.1 lM 4OOH-CPA (Fig. 5, A and C) , and this cH2AX signal was also significantly increased within the telomere region (Fig. 5, A and D) . In contrast, although treatment with 0.003 lM or 0.01 lM etoposide significantly increased the cH2AX signal intensity (Fig. 6 , A and C), this signal was not enriched in the telomere region. The cH2AX signal intensity was also significantly increased after treatment with 1.5 or 5 lM bleomycin (Fig. 7, A and C) ; after bleomycin exposure, like cisplatin and 4OOH-CPA, this cH2AX signal colocalized within the telomere region (Fig. 7, A and D) . Thus, exposures to cisplatin, 4OOH-CPA, and bleomycin all increased DNA damage in the telomere region of germ cells, whereas the DNA damage induced by etoposide was not enriched in this region.
DISCUSSION
The chemotherapeutic agents studied here are used widely in clinical practice for a variety of conditions ranging from non-Hodgkin lymphoma (cyclophosphamide, bleomycin) to testicular cancer (cisplatin, etoposide, bleomycin) or lung cancer (cisplatin, etoposide) [16] . It is known that chemotherapy negatively affects spermatogenesis, either transiently or permanently [30, 31] . Interestingly, it is also well established that there are similarities between cancer cells and those in the germ cell differentiation pathway [32] [33] [34] . One of these features is telomere maintenance for immortalization of both germ cells and cancer cells.
There is evidence in somatic cells that DNA-damaging agents affect telomeres. In tumor cells, treatment with cisplatin results in telomere length shortening [35] and telomerase activity inhibition [22] . In somatic cells and in tumor cells, treatment with etoposide [17] [18] [19] or bleomycin [20, 21] affects telomerase activity. Moreover, DNA damage is found in the telomere region after bleomycin treatment [15, 36] .
Telomeres are of critical importance in the maintenance of chromosome stability [8, 9] and are associated with aging [37] . It is reasonable to assume that damaging telomeres in gametes might affect the next generation. Moreover, telomere shortening is associated with elevated rates of early developmental failure [6] . Recently, it has also been reported that telomere length in male gametes is related to sperm numbers [38] . Our study is the first to assess the effects of alkylating agents (cisplatin and cyclophosphamide), a topoisomerase inhibitor (etoposide), and a cytotoxic antibiotic (bleomycin) on germ cell telomeres. Our data reveal that alkylating agents and bleomycin directly damage telomeres. Telomeres and the Terc gene may be at increased risk of the damage induced by alkylating agents, such as guanine DNA-DNA cross-links, because of their G-rich DNA sequences [39, 40] . Although the target of bleomycin is still unclear, there is evidence that bleomycin treatment can induce DNA damage to the telomere region [15, 36] .
Treatment with alkylating agents not only damages telomeres, but also inhibits telomerase activity. This inhibition is caused by reduced expression of both Tert and Terc. This is interesting because it has been reported previously that alkylating agents may affect not only DNA, but also RNA [41, 42] . Thus, we show three patterns of effects of chemotherapeutic agents on telomeres in C18-4 spermatogonial cells (Fig. 8) . The first pattern, after treatment with alkylating agents (cisplatin and cyclophosphamide), consists of DNA damage in both the telomere and nontelomere regions; this is accompanied by inhibition of telomerase and, as a consequence, a shortening of telomere lengths. In the second pattern, exemplified by bleomycin, DNA damage is found in both the telomere and nontelomere regions, but telomerase activity is not affected so the telomere lengths are not affected. In the third pattern, after etoposide treatment, DNA damage is induced, but this damage is not enriched in the telomere 
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regions and telomerase activity is not affected; the telomere lengths remain the same.
In the Terc gene knockout mouse, severe male sterility, caused by telomere shortening, was observed after the sixth generation [43] , but progressive defects in germ cells, with consequences on embryo development, were detected in the second generation [6] . Treatment of male rats with bleomycin, etoposide, and cisplatin induced adverse effects on progeny LIU ET AL.
during early embryonic development [44] . In cancer survivors, sperm DNA damage may persist 2 yr posttreatment with chemotherapeutic agents [1, 45] . These studies suggest that the treatment of spermatogonial cells (including spermatogonial stem cells) with chemotherapeutic agents may have long-term consequences, including telomere shortening and telomerase inhibition. Because the proliferation of spermatogonial cells is maintained after exposure to these drugs, it is important to establish the persistence of their effects on telomere structures and function in male germ cells and the possible transmission to and consequences on progeny.
In conclusion, our data demonstrate that alkylating agents and bleomycin damage germ cell telomeres; alkylating agents also inhibit telomerase activity. These findings raise concern about the potential risk of anticancer drugs to the next generation if telomere damage in gametes is sustained. Future studies are required to determine whether telomere damage is persistent during spermatogenesis and is transmitted to the next generation.
